Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.

Literature DB >> 26710351

Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.

Massimo Franchini¹, Enrico Capuzzo¹, Giancarlo M Liumbruno².

Abstract

Lipoprotein(a), which consists of a low-density lipoprotein (LDL) particle linked to an apolipoprotein(a) moiety, is currently considered an independent risk factor for cardiovascular disease due to its atherogenic (LDL-like) and prothrombotic (plasminogen-like) properties. The aim of this review is to provide an overview of the current and newer therapies for lowering increased lipoprotein(a) levels, focusing on lipoprotein apheresis. After a systematic literature search, we identified ten studies which, overall, documented that lipoprotein apheresis is effective in reducing increased lipoprotein(a) levels and cardiovascular events.

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26710351 PMCID： PMC5016300 DOI： 10.2450/2015.0163-15

Source DB: PubMed Journal: Blood Transfus ISSN： 1723-2007 Impact factor: 3.443

57 in total

Review 1. Lipoprotein apheresis.

Authors: Patrick M Moriarty; Linda Hemphill
Journal: Cardiol Clin Date: 2015-05 Impact factor: 2.213

2. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.

Authors: E Groß; B Hohenstein; U Julius
Journal: Atheroscler Suppl Date: 2015-05 Impact factor: 3.235

3. First data from the German Lipoprotein Apheresis Registry (GLAR).

Authors: Volker J J Schettler; Class L Neumann; Christian Peter; Thomas Zimmermann; Ulrich Julius; Eberhard Roeseler; Franz Heigl; Wolfgang Ramlow; Helmut Blume
Journal: Atheroscler Suppl Date: 2015-05 Impact factor: 3.235

4. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?

Authors: Adrian Rosada; Ursula Kassner; Anja Vogt; Michael Willhauck; Klaus Parhofer; Elisabeth Steinhagen-Thiessen
Journal: Artif Organs Date: 2013-07-25 Impact factor: 3.094

Review 5. Lipoprotein apheresis: state of the art and novelties.

Authors: C Stefanutti; U Julius
Journal: Atheroscler Suppl Date: 2013-01 Impact factor: 3.235

6. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors: Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal: Lancet Date: 2012-11-02 Impact factor: 79.321

Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.

Review 1. Lipoprotein apheresis.

2. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.

3. First data from the German Lipoprotein Apheresis Registry (GLAR).

4. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?

Review 5. Lipoprotein apheresis: state of the art and novelties.

6. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

7. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.

Review 8. Lipoprotein(a), cardiovascular disease, and contemporary management.

9. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.

10. Lipoprotein(a)-clinical aspects and future challenges.

Review 1. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.

Review 2. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.